WO2005120525A1 - Pharmazeutischer wirkstoff aus lycosa tarantula - Google Patents
Pharmazeutischer wirkstoff aus lycosa tarantula Download PDFInfo
- Publication number
- WO2005120525A1 WO2005120525A1 PCT/DE2004/001189 DE2004001189W WO2005120525A1 WO 2005120525 A1 WO2005120525 A1 WO 2005120525A1 DE 2004001189 W DE2004001189 W DE 2004001189W WO 2005120525 A1 WO2005120525 A1 WO 2005120525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- spiders
- peptide toxin
- poison
- family
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- biogenic poisons For the ingestion of food for the preservation of life, every living being is dependent on the offer from the accessible plant and animal kingdom. But not everything is safe to eat here. Many plants and animals use so-called biogenic poisons to protect their own life and to acquire food for their specific organism and special needs. These biogenic poisons have found their place in the interplay of different types of life in the course of long development periods.
- tumors if reasonably attainable, are in principle cut out with the steel of a knife, burned by a wide range of radiation, or destroyed by so-called chemotherapy with aggressive cytostatics that also attack healthy cells.
- a pharmaceutical active ingredient is known from DE 19961 141 A1, in which it was found that components of the spider venom from spiders of the Sicaridae family can be used for the treatment of tumor diseases.
- a peptide toxin from the poison of this type of spider, a further antagonistic substance obtained from the poison and / or a combination of these components are used medically.
- This active ingredient can be used for the treatment of tumor diseases and in parallel or in support of tumor operations and residual tumor tissue can be destroyed.
- genetically modified body cells tumor cells
- the total poison content of this type of spider, a cocktail of various substances, so to speak, is lethal due to its low doses, cannot be used pharmaceutically.
- breast carcinoma breast carcinoma
- Tarantella This epidemic broke out every summer for over three hundred years and was attributed to the bite of a large, hairy spider, the wolf spider. It was only in 1600 that the harmlessness of this type of spider was found.
- Lycosa tarantula is one of the physically largest spiders in Europe and belongs to the
- This type of spider does not catch its prey in webs but reaches them while walking due to the speed of its legs. It lives in a self-dug hole in the ground, which it covers in winter with a layer of cobwebs. Lycosa tarantula is about 5 cm tall and cannot be dangerous to people.
- the peptide toxin and the substance having an antagonistic effect thereon and / or the penetrating substance can be obtained by fractionation methods known per se for separating proteins from the crude spider venom mixture (spider venom cocktail). It is preferred here that the peptide toxin and the substance having an antagonistic effect on it are obtained by gel chromatography, HPLC, affinity chromatography and / or ion exchange chromatography.
- the antagonistic substance and / or the penetrating substance is preferably a phospholipase or a hyaluronidase or a combination of both substances. It is also preferred that the peptide toxin and the substance having an antagonistic effect thereon and / or the penetrating substance are present as an active pharmaceutical ingredient in such an amount that the active ingredient has a destructive effect on tumor cells. Furthermore, the required proportions are chosen so that the peptide toxin has no or only a slight toxic effect in the patient to be treated. Of course, the amounts of the active pharmaceutical ingredients must also be matched to the type of tumor to be treated and the physical, possibly also psychological, circumstances of the respective patient. The preliminary tests required for such a coordination are to be carried out by the specialist on the basis of his technical knowledge and ability.
- the amount of the penetrating substance is preferably chosen so that it largely recognizes the degenerated cells and selectively destroys the tumor cells in connection with the peptide toxin, healthy cells being largely preserved.
- the pharmaceutical active ingredient contains conventional carriers and auxiliary substances, such as antibiotics, antifungals, antituberculotics, agents against parasites, cytostatics, amino acids, enzymes which promote wound healing and / or mitotic inhibitors.
- antibiotics such as antibiotics, antifungals, antituberculotics, agents against parasites, cytostatics, amino acids, enzymes which promote wound healing and / or mitotic inhibitors.
- Penicillin / streptomycin, polynyxin / gentamycin (5%), mitopodocide, vinca rosea alkaloids, bromelaina or bromelains are preferred.
- the pharmaceutical active ingredient according to the invention is used in combination from the partial active ingredients described.
- the described partial active substances chemically and synthetically or by recombinant means using genetic engineering methods.
- the present invention also includes derivatives and salts of the substances provided according to the invention.
- the peptide toxin can comprise one or more substitutions and / or deletions of amino acids, it naturally having to be ensured that the medicinal effect according to the invention is retained.
- the partial active substances described are obtained by methods customary in chemical process engineering.
- part of the phospholidases can advantageously be removed from the total poison
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04738641A EP1758602A1 (de) | 2004-06-09 | 2004-06-09 | Pharmazeutischer wirkstoff aus lycosa tarantula |
US11/629,342 US20090220478A1 (en) | 2004-06-09 | 2004-06-09 | Pharmaceutical active substance |
PCT/DE2004/001189 WO2005120525A1 (de) | 2004-06-09 | 2004-06-09 | Pharmazeutischer wirkstoff aus lycosa tarantula |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/DE2004/001189 WO2005120525A1 (de) | 2004-06-09 | 2004-06-09 | Pharmazeutischer wirkstoff aus lycosa tarantula |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005120525A1 true WO2005120525A1 (de) | 2005-12-22 |
Family
ID=34958447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2004/001189 WO2005120525A1 (de) | 2004-06-09 | 2004-06-09 | Pharmazeutischer wirkstoff aus lycosa tarantula |
Country Status (3)
Country | Link |
---|---|
US (1) | US20090220478A1 (de) |
EP (1) | EP1758602A1 (de) |
WO (1) | WO2005120525A1 (de) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001043754A2 (de) * | 1999-12-17 | 2001-06-21 | Mack, Gerd, R. | Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen |
-
2004
- 2004-06-09 US US11/629,342 patent/US20090220478A1/en not_active Abandoned
- 2004-06-09 WO PCT/DE2004/001189 patent/WO2005120525A1/de active Application Filing
- 2004-06-09 EP EP04738641A patent/EP1758602A1/de not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001043754A2 (de) * | 1999-12-17 | 2001-06-21 | Mack, Gerd, R. | Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen |
Non-Patent Citations (1)
Title |
---|
N.N.: "Homöopathisches Repetitorium, Tarantula", 1987, DEUTSCHE HOMÖOPATHIE UNION, KARLSRUHE, XP002307491 * |
Also Published As
Publication number | Publication date |
---|---|
EP1758602A1 (de) | 2007-03-07 |
US20090220478A1 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10328251A1 (de) | Pharmazeutischer Wirkstoff | |
EP1758602A1 (de) | Pharmazeutischer wirkstoff aus lycosa tarantula | |
DE10324861A1 (de) | Pharmazeutischer Wirkstoff | |
WO2006029605A1 (de) | Verfahren und wirkstoff zur bekämpfung von plasmodien | |
WO2004108147A1 (de) | Pharmazeutischer wirkstoff | |
EP2155335B1 (de) | Pharmazeutische zusammensetzung, verwendung der pharmazeutischen zusammensetzung zur behandlung eines hirntumors, herstellungsverfahren derselben sowie ein kit of parts, enthaltend die pharmazeutische zusammensetzung | |
DE10357970A1 (de) | Lösungsmittel für biogene pharmazeutische Wirkstoffe | |
WO2007060252A2 (de) | Pharmazeutischer wirkstoff zur behandlung von hepatitis, borreliose und multipler sklerose | |
WO2004103384A1 (de) | Pharmazeutischer wirkstoff enthaltend ein peptidtoxin aus dem gift von schlangen der familie crotalus | |
DE10333192A1 (de) | Pharmazeutischer Wirkstoff gegen Warzen, Herpes simplex und Herpes zoster | |
WO2024132357A1 (de) | Pharmazeutische zusammensetzung zur behandlung eines hirntumors | |
DE10329847A1 (de) | Pharmazeutischer Wirkstoff gegen Prostatakarzinome | |
WO2005007177A1 (de) | Pharmazeutischer wirkstoff gegen magengeschwüre | |
WO2005027942A1 (de) | Pharmazeutischer wirkstoff aus schlangengift gegen melanome | |
WO2007071716A1 (de) | Pharmazeutische zusammensetzung zur behandlung von tumoren und bestimmten virenerkrankungen | |
DE10330712A1 (de) | Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten | |
WO2006134166A2 (de) | Pharmazeutischer wirkstoff zur überwindung der blut-hirn-schranke in verbindung mit einem aus biogenen giften gewonnenen wirkstoff gegen hirntumore | |
WO2006081808A1 (de) | Pharmazeutischer wirkstoff zur behandlung von multipler sklerose und aids | |
DE102004008417A1 (de) | Pharmazeutischer Wirkstoff gegen Lebertumore und Nierenzellkarzinome | |
DE102004019323A1 (de) | Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen | |
EP1754486A2 (de) | Pharmazeutischer Wirkstoff zur Behandlung von Hepatitis, Borreliose und Multipler Sklerose | |
DE102005027478A1 (de) | Pharmazeutischer Wirkstoff gegen Nierenzellkarzinome und dessen Lösungsmittel | |
EP1699472A1 (de) | Pharmarzeutischer wirkstoff gegen brustkrebs | |
WO2005002616A1 (de) | Pharmazeutischer wirkstoff gegen tumoren enthaltend loxoscelidae spinnengift | |
DE102005054918A1 (de) | Pharmarzeutischer Wirkstoff zur Behandlung von Tumorerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004738641 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1120040029376 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004738641 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004738641 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11629342 Country of ref document: US |